Navigation Links
Depomed Reports Third Quarter 2013 Financial Results
Date:11/5/2013

relations section of Depomed's website at http://www.depomed.com. Access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company's website for three months.

About DepomedDepomed, Inc. is a specialty pharmaceutical company with four approved and marketed products. Gralise® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia (PHN).  Zipsor® (diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug (NSAID) indicated for relief of mild to moderate acute pain in adults.
Lazanda® (fentanyl) Nasal Spray is an intranasal fentanyl drug used to manage breakthrough pain in adults (18 years of age or older) who are already routinely taking other opioid pain medicines around-the-clock for cancer pain.  Glumetza® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and is commercialized by Santarus, Inc. in the United States. Gralise and Glumetza and other product candidates are formulated with Depomed's proven, proprietary Acuform® drug delivery technology, which is designed to improve existing oral medications, allowing for extended release of medications to the upper gastrointestinal tract when dosed with food. Additional information about Depomed may be found on its website, www.depomed.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995. The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties including, but not limited to, those related to the commercialization of Gralise, Zipsor and Lazanda and other risks detailed in the company's Securities and
'/>"/>

SOURCE Depomed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Depomed To Report Third Quarter Fiscal Year 2013 Financial Results On Tuesday, November 5, 2013
2. Depomed Sells Type 2 Diabetes Royalties And Milestones To PDL BioPharma For $240.5 Million
3. PDL BioPharma Acquires Portfolio of Diabetes Royalty Rights and Milestones from Depomed
4. Depomed Expands Geographic Scope of License Agreement with Merck for Extended Release Metformin Patents
5. Depomed Reports Second Quarter 2013 Financial Results
6. Depomed To Report Second Quarter Fiscal Year 2013 Financial Results On Wednesday, August 7, 2013
7. FDA Grants Priority Review To New Drug Application For MNK-795 Submitted By Depomed Licensee Mallinckrodt
8. Depomed Announces Appointment of Louis J. Lavigne, Jr. to Board of Directors
9. Depomed to Present at Wells Fargo Securities 2013 Healthcare Conference
10. Depomed To Present At Jefferies 2013 Global Healthcare Conference
11. Depomed Reports First Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... NEW YORK and PLAINSBORO, ... Nordisk announced today its support of the National ... in Care , which provides support to people ... the physical and psychosocial challenges that can impede ... of six modules, Communication With Your Provider ...
(Date:9/18/2014)... and MELBOURNE, Australia , Sept. ... Biopharma today announced the appointments of Dr. Ashraf ... D.V.M ., M.S., to its Board of Directors. Dr. ... Affairs Finance at Genentech and Chief Financial Officer for ... as Vice President and Global Head of Business Development ...
(Date:9/18/2014)... NEW YORK , Sept. 18, 2014 ... novel therapies for the treatment of chronic pain, announced ... James to the position of  Senior Director of ... Clinical Research, Mr. James has established and led successful ... Europe , to facilitate the clinical development ...
Breaking Medicine Technology:Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 2Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 3Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development 2
... 2011 Egenix, Inc. -- Donald Fresne, CEO ... appointment of Nils Bergenhem, PhD as President and ... of drug development experience to the company and ... between equally-sized companies, as well as between biotech ...
... Caremark Corporation (NYSE: CVS ) will be ... at 8:30 a.m. (ET) with analysts and investors to ... (Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO) An audio webcast of the ... Relations portion of the CVS Caremark Web site for ...
Cached Medicine Technology:Nils Bergenhem, PhD - Newly Appointed President and Chief Scientific Officer of Egenix, Inc. 2CVS Caremark Corporation to Hold Second Quarter 2011 Conference Call 2
(Date:9/18/2014)... (PRWEB) September 18, 2014 Research conducted ... Allegheny Health Network has documented improved survival ... surgical removal of the tumors along with stereotactic radiosurgery. ... of ASTRO (American Society for Radiation Oncology) ... uses numerous precisely focused radiation beams to treat tumors ...
(Date:9/18/2014)... Johannesburg, South Africa (PRWEB) September 18, 2014 ... organization to adopt the HABIT™ Program in ... by Indaba Health and Wellness, and distributed in South ... version of the HABIT program, which has been tailored ... , IHW HABIT™ focuses on behavior modification and chronic ...
(Date:9/18/2014)... Springs, LA (PRWEB) September 18, 2014 This past ... got a kiss from Roy at the kissing booth during the ... “Bo” Bryant Animal Shelter. “I have loved animals my whole ... with most of those animals being strays who needed a home. ... animals since I can’t take them all home!” , The CEO ...
(Date:9/18/2014)... Ottawa (September 18, 2014) A new expert ... released today by the Council of Canadian Academies, ... medicines for children. Each year about half of ... prescription drug. Much of this prescribing is done ... use), creating potential health risks., Children have historically ...
(Date:9/18/2014)... study analyses the survival rates in Spain of newborns with ... survival under 23 weeks is ,exceptional, although other factors such ... Experts from the Spanish Society of Neonatology have studied the ... under 26 weeks, taking into account that a newborn carried ... data have been drawn from the national database that gathers ...
Breaking Medicine News(10 mins):Health News:Allegheny Health Network Study Shows Improved Survival in Patients with Metastatic Brain Cancer Who Undergo Surgical Excision Combined with Stereotactic Radiosurgery 2Health News:Allegheny Health Network Study Shows Improved Survival in Patients with Metastatic Brain Cancer Who Undergo Surgical Excision Combined with Stereotactic Radiosurgery 3Health News:Narconon New Life Retreat Supports Local Animal Shelter At Recent Fundraiser 2Health News:Improving medicines for children in Canada 2Health News:The viability of premature babies is minimal at 22 weeks' gestation 2
... test doesn,t single out those at high risk of trouble, ... screening for coronary artery disease is of no value for ... a new study finds. , Screening is expensive, at $1,000 ... 2 diabetes who had no symptoms of heart disease did ...
... Record 1,960 Eye and Tissue Donors in 2008 ... OneLegacy, the non-profit, federally designated organ and tissue ... area, has within the last year become the ... tens of thousands in need of cornea, bone, ...
... scientists at Beth Israel Deaconess Medical Center (BIDMC) have ... part of their 2009 Creativity Awards program, which supports ... prostate cancer. , The one-year awards were made ... with BIDMC the only institution in New England to ...
... April 14 While the number of ... the registry still only includes 38 percent of licensed ... Life America this year. Yet, according to a ... their decision to donate honored, even if their family ...
... Medical Plans, Inc., a leading provider-sponsored health insurer, covering ... announced an innovative Fracture Protection Pilot Program, in cooperation ... of Actonel, a prescription drug for the treatment and ... Alliance for Better Bone Health will cover the average ...
... (Nasdaq: ROCM ) will announce quarterly results after ... Company will then hold a quarterly conference call to discuss ... p.m. central time (5:00 p.m. eastern time).This call is being ... website at www.rocm.com . To listen ...
Cached Medicine News:Health News:Heart Screening Not Effective for Type 2 Diabetics 2Health News:Los Angeles Area Non-Profit OneLegacy Grows Into World's Largest Tissue Recovery Organization 2Health News:Los Angeles Area Non-Profit OneLegacy Grows Into World's Largest Tissue Recovery Organization 3Health News:Los Angeles Area Non-Profit OneLegacy Grows Into World's Largest Tissue Recovery Organization 4Health News:BIDMC scientists receive creativity awards from Prostate Cancer Foundation 2Health News:While the Majority of Americans Express Interest in Organ and Tissue Donation, Too Few Take Steps to Register as Donors 2Health News:While the Majority of Americans Express Interest in Organ and Tissue Donation, Too Few Take Steps to Register as Donors 3Health News:Health Alliance Announces First Fracture Protection Program for Actonel(R) (risedronate sodium) Tablets 2Health News:Health Alliance Announces First Fracture Protection Program for Actonel(R) (risedronate sodium) Tablets 3Health News:Health Alliance Announces First Fracture Protection Program for Actonel(R) (risedronate sodium) Tablets 4Health News:Rochester Medical Announces Second Quarter 2009 Earnings Conference Call April 30, 2009 2